Loading…
Aligos Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -98.6% over 5Y.
today you would have $14.21▼ -98.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $9.32 | $39.84 | $16.60 | $23.83 | $296.75 | $691.25 | |
| P/S | 26.3x | 26.3x | 42.6x | 8.1x | — | — | — |
| P/B | 1.1x | 1.1x | — | 0.5x | 0.4x | 2.7x | 4.8x |
| EPS | -$2.45 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| IXHLIncannex Healthcare Inc. | $3.64 | — | 0.7x | — | -117.17% | $43.55M |
| VERUVERU Inc | $2.50 | — | 1.5x | — | -64.54% | $42.63M |
| EDSAEdesa Biotech, Inc. | $4.62 | — | 112.7x | — | -122.93% | $44.54M |
| MLSSMilestone Scientific Inc | $0.50 |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Company description provided by Yahoo Finance.
| -$20.94 |
| -$34.20 |
| -$56.25 |
| -$80.50 |
| -$271.75 |
| Profit margin | -1416.23% | -1106.72% | -3633.65% | -1416.23% | — | — | — |
| ROE | -69.47% | -45.18% | — | -95.22% | -92.44% | -69.47% | -49.33% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 12.9x |
| — |
| -121.67% |
| $44.55M |
| GRCEGrace Therapeutics, Inc. | $2.12 | — | 0.7x | — | -36.19% | $44.6M |
| TVGNTevogen Inc. | $6.89 | — | — | — | — | $44.86M |